Lipids and Renal Disease
Open Access
- 1 April 2006
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of the American Society of Nephrology
- Vol. 17 (4_suppl_2), S145-S147
- https://doi.org/10.1681/asn.2005121320
Abstract
Chronic renal disease is accompanied by characteristic abnormalities of lipid metabolism, which appear as a consequence of nephrotic syndrome or renal insufficiency and are reflected in an altered apolipoprotein profile as well as elevated plasma lipid levels. Experimental and clinical studies have suggested a correlation between the progression of renal disease and dyslipidemia. High cholesterol and triglyceride plasma levels have been demonstrated to be independent risk factors for progression of renal disease in humans. The underlying pathophysiologic mechanisms for the relationship between lipid levels and progression of renal disease are not yet fully understood, although there are data that oxidative stress and insulin resistance may mediate the lipid-induced renal damage. In the animal model, lipid-lowering agents seem to ameliorate glomerular damage, preventing glomerulosclerosis and interstitial fibrosis. Although evidence from clinical studies indicates that statin therapy is associated with significant benefit in individuals with established chronic renal failure, whether lipid reduction can slow the renal functional decline awaits a primary renal outcome lipid-lowering therapy study.Keywords
This publication has 25 references indexed in Scilit:
- Lipoproteins in the DCCT/EDIC cohort: Associations with diabetic nephropathyKidney International, 2003
- Molecular mechanisms of lipid disorders in nephrotic syndromeKidney International, 2003
- Molecular mechanisms of altered cholesterol metabolism in rats with spontaneous focal glomerulosclerosisKidney International, 2003
- Effect of combining ACE inhibitor and statin in severe experimental nephropathyKidney International, 2002
- Plasma lipids and risk of developing renal dysfunction: The Atherosclerosis Risk in Communities StudyKidney International, 2000
- Prevalence and Risk Factors for Micro- and Macroalbuminuria in an Italian Population-Based Cohort of NIDDM SubjectsDiabetes Care, 1996
- Lovastatin inhibits proliferation of rat mesangial cells.JCI Insight, 1993
- Clustering of risk factors in hypertensive insulin-dependent diabetics with high sodium-lithium countertransportKidney International, 1992
- Plasma lipid and coagulation factor concentrations in insulin dependent diabetics with microalbuminuria.BMJ, 1989
- Microalbuminuria Predicts Clinical Proteinuria and Early Mortality in Maturity-Onset DiabetesThe New England Journal of Medicine, 1984